CHMP Recommends Variation To Pegasys MA

On March 20 2014, the EMA's CHMP adopted a positive opinion recommending a variation to the terms of the marketing authorisation (MA) for Roche's Pegasys (peginterferon alpha-2a).

The CHMP adopted a change to an indication as follows: ' Pegasys is indicated in combination with other medicinal products, for the treatment of chronic hepatitis C in patients with compensated liver disease.

CHMP Recommends Variation To Pegasys MA

On March 20 2014, the EMA's CHMP adopted a positive opinion recommending a variation to the terms of the marketing authorisation (MA) for Roche's Pegasys (peginterferon alpha-2a).

The CHMP adopted a change to an indication as follows: ' Pegasys is indicated in combination with other medicinal products, for the treatment of chronic hepatitis C in patients with compensated liver disease.

×

Enter your details to read the full article

By submitting this form you are acknowledging that you have read and understood our Privacy Policy.

×

REQUEST A DEMO

By submitting this form you are acknowledging that you have read and understood our Privacy Policy.

Thank you for your interest

A member of the team will be in touch shortly to arrange a convenient time for your free demonstration and trial. If your enquiry is urgent, please email our Client Services team here.